pulmatrix pipeline

 
Pulmatrix is advancing a pipeline of product candidates to treat serious pulmonary diseases. Our first-in-class anti-fungal product candidate for cystic fibrosis is the most advanced program in our pipeline of treatments for rare, orphan disease. In addition,
we are developing inhaled therapies for pulmonary diseases that affect large patient populations, such as chronic obstructive pulmonary disease (COPD) and asthma.
PUR1900 is an iSPERSE formulation incorporating a large, complex anti-fungal compound that can be administered at high therapeutic dose to the lung while minimizing systemic side effects. It is estimated that nearly 50% of patients with cystic fibrosis (CF) experience pulmonary fungal infections that can cause chronic bronchitis or allergic reactions, resulting in inflammation and poor long term outcomes. PUR1900 is the first inhaled anti-fungal product candidate for CF.

PUR1500 is an iSPERSE formulation incorporating a kinase inhibitor with established anti-angiogenesis activity for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive and generally fatal disease characterized by scarring of the lungs, causing an irreversible loss of the tissue’s ability to transport oxygen. PUR1500 intends to suppress the fibrotic pathway at the site of disease in the lung interstitium.

PUR0200 is an iSPERSE formulation incorporating a marketed long-acting muscarinic antagonist (LAMA) bronchodilator. It exemplifies the highly efficient delivery that iSPERSE can achieve. Because nearly all of the dose reaches the site of action in the lung and is not swallowed or otherwise lost, PUR0200 can achieve the same effect as the marketed product at 20% of the dose administered. PUR0200 is currently being developed in Europe based on PK bioequivalence, and the US development program is being planned.
 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design